



**Invitation
to the 2016 Annual General Meeting**

STADA Arzneimittel AG
Bad Vilbel, Germany

WKN 725180
ISIN DE0007251803

We hereby invite shareholders of our Company to the

**Annual General Meeting
to be held on August 26, 2016 at 10.00 a.m. (CEST)**

in the

**Congress Center Messe Frankfurt,
Congress Ebene C2, Saal Harmonie,
Ludwig-Erhard-Anlage 1,
60327 Frankfurt am Main,
Germany**

Agenda

Item 1 on the agenda

Submission of the adopted annual financial statements of STADA Arzneimittel AG and the consolidated financial statements as at December 31, 2015, of the management report of STADA Arzneimittel AG and the consolidated management report, the explanatory report of the Executive Board regarding the statements pursuant to section 289, para. 4 and section 315, para. 4 of the German Commercial Code (*Handelsgesetzbuch – HGB*) as well as the report of the Supervisory Board for financial year 2015

On March 22, 2016, the Supervisory Board approved the annual financial statements and the consolidated financial statements prepared by the Executive Board. The annual financial statements were thus adopted pursuant to section 172 of the German Stock Corporation Act (*Aktiengesetz – AktG*). In accordance with the law, no resolution of the Annual General Meeting is to pass on Agenda Item 1. The following documents, mentioned under this Agenda Item, will be made available to shareholders on the Internet at www.stada.com/agm2016 as from the date of the convening notice of the Annual General Meeting. They will also be displayed for inspection at the Annual General Meeting and be described in more detail:

- Adopted annual financial statements for financial year 2015 of STADA Arzneimittel AG
- Management Report for financial year 2015 of STADA Arzneimittel AG
- Approved consolidated financial statements for financial year 2015 of the STADA Group
- Consolidated Management Report for financial year 2015 of the STADA Group
- Report of the Supervisory Board for financial year 2015
- Executive Board's proposal for the appropriation of the balance sheet profits of financial year 2015
- Explanatory report of the Executive Board regarding the statements pursuant to section 289, para. 4 and section 315, para. 4 of the German Commercial Code

Item 2 on the agenda

Resolution on the appropriation of the balance sheet profits

The Executive Board and the Supervisory Board propose to allocate the balance sheet profits of financial year 2015 in the amount of EUR 59,139,388.83 as follows:

1. Dividend distribution of EUR 0,70 per share entitled to dividend (62,256,520 existing shares entitled to dividend)	EUR	43,579,564.00
2. Profit carried forward to new account	EUR	15,559,824.83
Balance sheet profits	EUR	59,139,388.83

The amounts stated for the total dividend and the amount to be carried forward are based on the dividend-entitled shares as of the date of the allocation-proposal. Pursuant to section 71b of the German Stock Corporation Act, the Company's treasury shares are not dividend-entitled. If the number of dividend-entitled shares changes until the date of the Annual General Meeting, the Annual General Meeting shall be submitted with an accordingly adjusted proposal on the allocation of the profits. This proposal will provide for an unchanged distribution of EUR 0,70 per dividend-entitled share as well as correspondingly adjusted payout and amount to be carried forward.

The dividend will be distributed on August 29, 2016.

Item 3 on the agenda

Resolution formally approving the activities of the members of the Executive Board for financial year 2015

The Executive Board and the Supervisory Board propose to approve the activities of the members of the Executive Board, who were acting in 2015, for financial year 2015.

Item 4 on the agenda

Resolution formally approving the activities of the members of the Supervisory Board for financial year 2015

The Executive Board and the Supervisory Board propose to approve the activities of the members of the Supervisory Board, who were acting in 2015, for financial year 2015.

Item 5 on the agenda

Resolution on the election of the external auditor for the annual and consolidated financial statements of the financial year 2016

The Supervisory Board proposes upon recommendation of its audit committee that PKF Deutschland GmbH, Wirtschaftsprüfungsgesellschaft, Hamburg, be elected as auditor for the annual and consolidated financial statements for the financial year 2016.

Resolution on the approval of the system for the remuneration of members of the Executive Board

Pursuant to Section 120 para. 4 of the German Stock Corporation Act, the Annual General Meeting may – without creation of rights and obligations – resolve about the approval of the system for the remuneration of members of the Executive Board. Such a resolution was taken at last by the Company's Annual General Meeting on June 16, 2011. The system for the remuneration of members of the Executive Board was redesigned with effect from January 1, 2016. For this reason the system shall be presented for approval at this year's Annual General Meeting.

The revised system for the remuneration of members of the Executive Board is described in the remuneration report 2015 under "Structure of the Executive Board remuneration system since January 1, 2016". This section of the remuneration report, which is part of the management report for the financial year 2015, is printed from page 114 in the Annual Report 2015. The Annual Report 2015 is available on the Internet at www.stada.com/agm2016 and will be available for inspection at the Annual General Meeting.

The system for the remuneration of the members of the Executive Board had been evaluated by the auditor Ernst & Young GmbH, Hamburg, by the international law company Freshfields Bruckhaus Deringer LLP, and by the personnel consulting firm Towers Watson GmbH, Frankfurt am Main. A summary of these external evaluations is available on the Internet at www.stada.com/agm2016.

The Executive Board and the Supervisory Board propose to approve the redesigned system for the remuneration of the members of the Executive Board, which is portrayed in the "remuneration report 2015".

Resolution on the elimination of restrictions on the transferability of registered shares in STADA Arzneimittel AG, corresponding amendments to the Articles of Association as well as a relevant adjustment to the existing authorization for the Executive Board to issue bonds with warrants and/or convertible bonds, participation rights and/or participating bonds and the associated Conditional Capital 2013 pursuant to the resolution of the Annual General Meeting of June 5, 2013

In accordance with section 5 of the Articles of Association, the share capital of the company consists of registered shares with restricted transferability (no-par value shares), which are only transferable with the approval of the Executive Board, in accordance with section 8, para. 1 of the Articles of Association. It is intended to eliminate the limitations on the transferability of registered shares and to change the affected regulations in the Articles of Association accordingly. In this context, the existing authorization of the Executive Board to issue bonds with warrants and/or convertible bonds, participation rights and/or participating bonds and the associated Conditional Capital 2013 pursuant to the resolution of the Annual General Meeting of June 5, 2013 is also to be adapted accordingly.

The Executive Board and the Supervisory Board propose to pass the following resolution:

- a) Restrictions on the transferability of the registered shares in accordance with section 8 para. 1 of the Articles of Association of the Company are to be repealed. The Articles of Association of the Company shall be amended as follows:
 - In section 5 of the Articles of Association (*share capital*), the words "registered shares with restricted transferability" shall be replaced with the words "registered shares".
 - In para. 1 and para. 2 from section 6 of the Articles of Association (*authorized and conditional capital*), the words "registered shares with restricted transferability" shall be replaced with the words "registered shares" each time they appear.

- Para. 1 from section 8 of the Articles of Association (*shares and share classes*) shall be deleted without replacement. The previous para. 2 and 3 from section 8 of the Articles of Association shall become para. 1 and 2 and remain otherwise unchanged. The heading of section 8 of the Articles of Association shall be changed to "*shares*".
- In section 24 of the Articles of Association (*voting rights*), the words "registered share with restricted transferability" shall be replaced with the words "registered share".

b) Further, with effect on the entry of the upcoming amendments to the Articles of Association in the commercial register of the Company

- the authorization for the Executive Board to issue bonds with warrants and/or convertible bonds, participation rights and/or participating bonds pursuant to the resolution of the Annual General Meeting of June 5, 2013 on item 7 of the agenda shall be adapted to the extent that the relevant bonds with warrants and/or convertible bonds correlate to the registered shares instead of the registered shares with restricted transferability; and
- the corresponding Conditional Capital 2013 created with the resolution of the Annual General Meeting of June 5, 2013 on item 7 of the agenda shall be adapted to the extent that it regulates the conditional issue of registered shares instead of the issue of registered shares with restricted transferability and, in this connection, in the Conditional Capital 2013, the words "registered shares with restricted transferability" shall be replaced with the words "registered shares".

Apart from this, the authorizations and the Conditional Capital 2013 mentioned shall remain unchanged in their respective scope and form at the time the adjustment takes effect.

Resolution on new elections to the Supervisory Board

The Supervisory Board members Dr. Eckhard Brüggemann, Dr. K. F. Arnold Hertzsch, Dieter Koch and Constantin Meyer have resigned from their position as shareholder representatives, effective at the end of the Annual General Meeting on August 26, 2016, and will leave the Supervisory Board of the company at this time. The resigning Supervisory Board members were elected by the Annual General Meeting of 2013 for a term until the conclusion of the Annual General Meeting, which decides upon the approval of activities for the 2017 financial year.

The Supervisory Board consists in total of nine members pursuant to section 96, para. 1, section 101, para. 1 of the German Stock Corporation Act, section 1, para. 1, no. 1, section 4, para. 1 of the German One-Third Participation Act (Drittelbeteiligungsgesetz) and section 12, para. 1 of the Articles of Association. Six of them shall be elected by the Annual General Meeting.

Pursuant to section 12, para. 2 of the Articles of Association, the election is principally for a period ending upon the conclusion of the Annual General Meeting which decides on the approval for the fourth financial year following the election, whereby the year of election is not included. If a member of the Supervisory Board elected by the Annual General Meeting leaves the Supervisory Board before the completion of its term of office, pursuant to section 12, para. 3 of the Articles of Association a new election is to be held at the next Annual General Meeting, whereby the term of office of the newly elected member is equivalent to the remaining term of office of the departing member. With the non-compliance with section 12, para. 3 of the Articles of Association, the election shall be held for the period until the end of the Annual General Meeting, which decides on the approval of financial year 2020, and thus beyond the period of the remaining term of office of the departing Supervisory Board member. This is to ensure sustained completion of Supervisory Board tasks for both the company and the new candidates.

The following candidate recommendations are based on the profile of requirements developed by the Nomination Committee of the Supervisory Board and resolved upon by the Supervisory Board (its shareholder representatives).

The Supervisory Board therefore recommends – in each case in accordance with the recommendations of the Nomination Committee – that,

- a) Ms. Dr. Birgit Kudlek, Bad Soden, member of the Supervisory Board of WILEX AG, former Managing Director and Chief Operating Officer, Aenova Holding GmbH, Starnberg, Germany (until October 2015),
- b) Ms. Tina Müller, Frankfurt am Main, Managing Director Marketing, Chief Marketing Officer, Opel Group GmbH, Rüsselsheim, Germany,
- c) Mr. Dr. Gunnar Riemann, Berlin, independent Business Consultant in the Life Science Industry, former President of the Division Environmental Science, Bayer CropScience AG, Monheim am Rhein, Germany (until April 2015),
- d) Mr. Rolf Hoffmann, Weggis, Switzerland, Senior Vice President of US Commercial Operations, Amgen, Thousand Oaks, California, USA (until 31 July 2016); adjunct professor at University of North Carolina Kenan-Flagler Business School, Chapel Hill, USA (since end of June 2016).

are elected as Supervisory Board members respectively effective from the end of the Annual General Meeting on August 26, 2016. In accordance with section 12, para. 3 of the Articles of Association, the election is in any case to be until the end of the Annual General Meeting which decides on the approval of the financial year concluding on December 31, 2017, and, in addition, in accordance with this resolution and in contradiction to section 12, para. 3 of the Articles of Association, until the conclusion of the Annual General Meeting which decides on the approval of the fourth financial year after the current election; the current financial year is not included. The maximum permitted duration of a term of office of a Supervisory Board member in accordance with section 12, para. 2 of the Articles of Association and section 102, para. 1 of the German Stock Corporation Act is thereby ensured and complied with.

The Annual General Meeting is not bound by nominations when electing shareholder representatives. It is intended to allow the Annual General Meeting to decide on new elections to the Supervisory Board by way of a separate vote.

You will find more detailed information on the careers of the candidates as well as on the profile of requirements and the selection process in the CVs and the information available on the Internet at www.stada.com/agm2016.

Additional information on item 8 about the Supervisory Board candidates in accordance with section 125 para. 1 sentence 5 of the German Stock Corporation Act

The candidates Ms. Dr. Birgit Kudlek and Ms. Tina Müller recommended under item 8 are members of the following statutory Supervisory Boards:

Ms. Dr. Birgit Kudlek

- Supervisory Board of WILEX AG

Ms. Tina Müller

- Supervisory Board of MLP AG

Ms. Dr. Birgit Kudlek and Ms. Tina Müller do not hold any memberships in similar German and foreign Supervisory Bodies of commercial enterprises. Mr. Dr. Gunnar Riemann and Mr. Rolf Hoffmann have no memberships in any statutory Supervisory Boards or similar German and foreign Supervisory Bodies of commercial enterprises.

Additional information on item 8 in accordance with section 5.4.1 para. 5 to 7 of the German Corporate Governance Code

Pursuant to clause 5.4.1 of the German Corporate Governance Code, it is hereby declared that, in the opinion of the Supervisory Board, none of the recommended candidates have personal or commercial relationships to the Company or its Group companies, Boards of the Company or a shareholder with a significant stake in the Company.

Total amount of shares and voting rights

At the convening of the Annual General Meeting, the Company has a share capital of EUR 162,090,344.00; it is divided into 62,342,440 registered shares with restricted transferability with no-par value representing an arithmetical share of the share capital of EUR 2.60 per share. Each share grants entitlement to one vote. The Company holds 85,920 treasury shares at the date of the convening notice. There is a total amount of shares with participation and voting rights of 62,256,520.

Preconditions for participating in the meeting and exercising voting rights

Only those shareholders are entitled to attend the Annual General Meeting and to exercise the voting right in the Annual General Meeting who are registered in the Company's share register on the day of the Annual General Meeting and have notified their attendance such that their notice of attendance has been received by the Company at the latest by August 19, 2016, 24.00 (CEST) at the address below:

STADA Arzneimittel AG
c/o HCE Haubrok AG
Landshuter Allee 10
80637 Munich
Germany
Fax: +49 (0) 89/21027288

The notice of attendance of the shareholder can also be electronically submitted at the latest by August 19, 2016, 24.00 (CEST) via an electronic Internet form provided by the Company at www.stada.com/agm2016 or to the e-mail hv2016@stada.de. The individual access information for the use of the electronic Internet form with password protection will be sent to the shareholders with the Invitation to the Annual General Meeting.

Pursuant to section 67, para. 2, sentence 1 of the German Stock Corporation Act, in relation to the Company, only a person who has been registered as such in the share register shall be deemed a shareholder. Accordingly, the registration status of the share register on the day of the Annual General Meeting will be decisive for determining participation and voting rights. For technical reasons,

applications for changes to the Company's share register will not be registered during the period of August 20, 2016, 0.00 (CEST) through August 26, 2016, 24.00 (CEST). For this reason the state of registrations in the share register to exercise the participation and voting rights on the day of the Annual General Meeting will correspond to the state of registrations after the last registration day on August 19, 2016, 24.00 (CEST). Technical cut-off date (so called Technical Record Date) will therefore be the end of August 19, 2016. The registration for the Annual General Meeting does not result in the shares being blocked; the shareholders are still free to make dispositions in respect of the shares after registration. Purchasers of shares whose applications for change of registration were received by the Company after August 19, 2016, 24.00 (CEST) can therefore not exercise their participation and voting rights arising out of these shares, unless they have obtained a power of attorney to do so or an authorization to exercise such rights. In such cases, participation and voting rights remain with the shareholder registered in the share register until the change in registration.

Upon timely reception of the notice of attendance, the admission ticket for the Annual General Meeting will be issued and sent to the shareholder. The admission ticket will be exchanged for a ballot paper at the hall entrance prior to the beginning of the Annual General Meeting. The convening of the Annual General Meeting including the agenda along with the documents concerning registration and/or granting of proxy will be sent by the Company unsolicited to all shareholders who are listed in the share register at least on the 14th day prior to the day of the Annual General Meeting.

Credit institutions and shareholders' associations as well as other persons, institutes or companies of equal status pursuant to section 135 para. 8 or section 135 para. 10 in conjunction with section 125 para. 5 of the German Stock Corporation Act may exercise voting rights arising under registered shares which they do not hold, but with respect to which they are registered in the share register as shareholder, only pursuant to an authorization of the shareholder. Details on these authorizations can be found in section 135 of the German Stock Corporation Act.

Further information about the notification process can be found on the Invitation to the Annual General Meeting sent to all shareholders.

Procedure for exercising voting rights by a proxy holder

Shareholders may exercise their voting rights in the Annual General Meeting by a proxy holder, e.g. a credit institution, a shareholders' association or by a person of their choice as well as by the proxy representative or a member of the Advisory Board of the Company. If the shareholder authorizes more than one person, the Company may reject one or more of such persons. Authorization of a proxy also requires notice of application in a timely manner.

Authorization of a third party

The granting of proxy, its revocation and proof towards the Company must be provided in text form pursuant to section 134 para. 3, sentence 3 of the German Stock Corporation Act. In the event that a credit institution, a shareholders' association or another person or institution of equal status pursuant to § 135 para. 8 or section 135 para. 10 in conjunction with section 125 para. 5 of the German Stock Corporation Act is to be appointed proxy, neither the law nor the Articles of Association stipulate a particular form requirement.

Shareholders may use the "Registration Sheet to the Annual General Meeting 2016" sent together with the Invitation to the Annual General Meeting for granting of proxy. Shareholders may also issue a separate authorization. An authorization form for this purpose is also available on the Internet at www.stada.com/agm2016.

Notwithstanding any other legally permitted method of transmission of the proof of authorization of a proxy to the Company, such proof may be electronically transmitted by using a password-protected Internet form at www.stada.com/agm2016 or to the e-mail hv2016@stada.de. The individual password for the use of the electronic Internet form with password protection will be sent to the shareholders with the Invitation to the Annual General Meeting.

Specific rules have to be observed when authorizing credit institution or institutes or companies of equal status pursuant to section 135 para. 10 in conjunction with section 125 para. 5 of the German Stock Corporation Act as well as shareholders' associations or persons of equal status pursuant to section 135 para. 8 of the German Stock Corporation Act; details should be requested from the party to be authorized. By law, the authorization must be granted to a certain

proxy holder and recorded by the proxy holder in a verifiable manner. In addition, the form of proxy shall be completed in full and may only contain statements related to the exercise of voting rights. We therefore ask you to come to an agreement with the intended proxy about the form of the authorization in case you wish to authorize a credit institution, a shareholders' association or another person of equal status pursuant to section 135 of the German Stock Corporation Act. Under section 135 of the German Stock Corporation Act, violation of the aforementioned and certain other requirements for authorization of those named in this paragraph, does, however, not affect the validity of the vote pursuant to section 135 para. 7 of the German Stock Corporation Act.

Exercising voting rights through a proxy representative of the Company or an Advisory Board member of the Company

We offer our shareholders the special service of being represented by the proxy representative of the Company or an Advisory Board member of the Company. Under the Articles of Association, the Advisory Board shall have the specific duty to be at the disposal of the shareholders who do not wish to exercise their rights in the Annual General Meeting in person, and to act as their authorized representative in the Annual General Meeting. For that purpose, the proxy representative or Advisory Board member must receive authorization as well as express and clear instructions for exercising the vote on each relevant item of the agenda. In case of absence of express and clear instructions, the proxy representative or Advisory Board member shall abstain from voting on the relevant voting item. In the event that individual ballots are conducted in respect of an Agenda Item, any instruction issued in this regard will apply accordingly in respect of each individual sub-item. The proxy representative and Advisory Board members are obliged to follow voting instructions. They will not accept any instructions relating to requests to speak, asking questions or bringing forward motions or nominations, or the filing of objections against resolutions by the Annual General Meeting.

Authorization and voting instructions to the proxy representative named by the Company or the Advisory Board members may be granted in text format using the authorization and instruction form for that purpose on the "Registration Sheet to the Annual General Meeting 2016" enclosed with the Invitation to the Annual General Meeting, via an electronic Internet form with password protection

at www.stada.com/agm2016 or to the e-mail hv2016@stada.de. Authorizations and instructions in text format to proxy representative of the Company or the Advisory Board members must have been received by the Company at the following address:

STADA Arzneimittel AG
Legal Department
Stadastraße 2-18
61118 Bad Vilbel
Germany
Fax: +49 (0) 6101/603 611970
E-mail: hv2016@stada.de

All other permitted modes of attendance and representation, in particular attendance in person or attendance through an authorized representatives will, of course, not be affected by this offer to exercise voting rights through the proxy representative named by the Company or an Advisory Board member.

More details about authorizing and instructing the proxy representative named by the Company or an Advisory Board member will be sent together with the invitation to the Annual General Meeting. Similar information may also be viewed on the Internet at www.stada.com/agm2016.

**Rights of the shareholders pursuant
to section 122 para. 2, 126 para. 1, 127, 131 para. 1
of the German Stock Corporation Act**

**Requests for supplements to the agenda pursuant to section
122 para. 2 of the German Stock Corporation Act**

Shareholders whose shares amount in aggregate to not less than a twentieth of the share capital or represent an amount of the share capital corresponding to EUR 500,000.00, may demand that items are put on the agenda and published. Each new item shall be accompanied by an explanation or a draft proposal. Such requests are to be addressed in writing to the Executive Board of STADA Arzneimittel AG and must be received by the Company at least 30 days before the Annual General Meeting, i.e., at the latest by July 26, 2016, 24.00 (CEST). Please send such requests to the following address:

STADA Arzneimittel AG
Executive Board
Stadastraße 2-18
61118 Bad Vilbel
Germany

Those submitting such requests must document that they have been the owners of the shares for the duration of at least 90 days prior to the day of the receipt of the request and hold the shares until such time as a decision of the Executive Board is rendered regarding their request (sections 122 para. 2, 122 para. 1 sentence 3 of the German Stock Corporation Act as well as section 70 of the German Stock Corporation Act).

The announcement and provision of requests for supplements is carried out in the same way as convening notices.

Motions and nominations by shareholders pursuant to sections 126 para. 1, 127 of the German Stock Corporation Act

Shareholders of the Company may submit countermotions against proposals of the Executive Board and the Supervisory Board with respect to specific Agenda Items as well as nominations for the election of the auditor and the Supervisory Board. If countermotions are meant to be made accessible, they must include an explanatory statement; nominations do not require an explanatory statement.

Countermotions regarding to the agenda and nominations must be exclusively forwarded to the Company's following address:

STADA Arzneimittel AG
Legal Department
Stadastraße 2-18
61118 Bad Vilbel
Germany
Fax: +49 (0) 6101/603 611970
E-mail: hv2016@stada.de

Any countermotions and nominations received by the Company at the aforementioned address no later than 14 days before the day of the Annual General Meeting, i.e. by August 11, 2016, 24.00 (CEST), will be published immediately after receipt on the Internet at

www.stada.com/agm2016 including the name of the shareholder and – in case of motions – including the explanatory statement under the further conditions of sections 126, 127 of the German Stock Corporation Act. Possible statements of the administration will also be published at the same internet address.

Right to information in accordance of section 131 para. 1 of the German Stock Corporation Act

Each shareholder shall upon request be provided with information at the Annual General Meeting by the Executive Board regarding the Company's affairs, to the extent that such information is necessary to permit a proper evaluation of the relevant Agenda Item. The request for information shall also extend to the Company's legal and business relations with any affiliated enterprise as well as the outlook of the Group and the companies included in the consolidated financial statements.

Further information on the rights of the shareholders

Further information on the rights of the shareholders pursuant to sections 122, para. 2, 126 para. 1, 127, 131 para. 1 of the German Stock Corporation Act can be found on the Internet at www.stada.com/agm2016.

Reference to the Company's Internet page

Information shall be made available to the shareholders of the Company in accordance with section 124a of the German Stock Corporation Act on the Company's Internet page at www.stada.com/agm2016.

The invitation to the Annual General Meeting shall be published in the Federal Bulletin (*Bundesanzeiger*) dated July 20, 2016.

Bad Vilbel, July 2016

STADA Arzneimittel AG

The Executive Board

Route planner to the Annual General Meeting

Arriving by car*:

Autobahn A5 from Kassel and Basel/Mannheim:

Exit at Frankfurt Westkreuz to the A648 following the signs to "Stadtmitte/Messe", then the signs to "Stadtmitte/Congress C.".

Autobahn A3 from Würzburg:

Cross over Frankfurter Kreuz on the A5, exit at Frankfurt Westkreuz to the A648 in direction to "Stadtmitte/Messe" and follow the signs to "Stadtmitte/Congress C.".

Autobahn A3 from Cologne:


At Wiesbadener Kreuz follow the A66 towards Frankfurt, then follow the signs to "Stadtmitte/Congress C." on the A648.

The number of parking spaces in the Messe Congress Center car park is limited.

Arriving by train/tram:

To Frankfurt am Main central station, then take the U4 tube to the "Festhalle/Messe" station or take tram line 16 or 17 to the "Festhalle/Messe" tram stop.

We like to inform you that STADA Arzneimittel AG will neither bear the expenses for parking nor for RMV-tickets.



In the interest of all participants, we will establish security measures that are customary for assemblies of this kind. This will include, among other things, a utilising a metal detector at the entrance to the meeting. In this connection, we ask you not to carry any dangerous items such as knives or scissors, since we will have to secure them into safekeeping until you leave the shareholders' meeting. We appreciate your understanding in this context. Also, please keep in mind that there could possibly be delays at the entrance to the meeting place – despite comprehensive preparations by the company. We hereby inform you that shareholders are not permitted to make video or audio recordings as well as stenographic transcripts.

*Please note: On October 1, 2008, the city of Frankfurt am Main introduced a low emission zone to mitigate the emission of particles (fine particles), in order to adhere to the threshold values under the German Federal Immission Control Act (Bundes-Immissionsschutzgesetz, BImSchG). From January 1, 2012 on only vehicles marked with green sticker are permitted to enter the low emission zone. Frankfurt's low emission zone is the area within the highway belt created by the A5 in the West, the A3 in the South and the A661 in the East and North.



STADA Arzneimittel Aktiengesellschaft

Stadastraße 2-18 61118 Bad Vilbel Phone +49 (0)6101 603-0
Internet: www.stada.com

Chairman Supervisory Board:

Dr. Martin Abend

Executive Board: Dr. Matthias Wiedenfels (Chief Executive Officer)

Helmut Kraft

Hartmut Retzlaff (exempted from duty)

Registered Office: Bad Vilbel

District Court: Frankfurt/Main, HRB 71290